Kazia Therapeutics Files 6-K Report
Ticker: KZIA · Form: 6-K · Filed: May 1, 2024 · CIK: 1075880
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, pharmaceuticals
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed a routine 6-K, confirming its status as a foreign private issuer.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on May 1, 2024. The company, based in Sydney, NSW, is a pharmaceutical preparations company and is required to file annual reports under Form 20-F. This filing is for the month of May 2024.
Why It Matters
This filing indicates Kazia Therapeutics is a foreign private issuer and adheres to SEC reporting requirements for companies like it.
Risk Assessment
Risk Level: low — This is a standard regulatory filing for a foreign private issuer and does not contain new financial or operational information.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- May 1, 2024 (date) — Filing date
- Sydney NSW (location) — Company address
- Form 20-F (document) — Annual report form
- Form 6-K (document) — Report type
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to report material information that is made public in their home country.
What is Kazia Therapeutics Limited's former name?
Kazia Therapeutics Limited's former name was Novogen Ltd, with a date of name change on December 28, 1998.
Where is Kazia Therapeutics Limited headquartered?
Kazia Therapeutics Limited is headquartered at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Which annual report form is Kazia Therapeutics Limited required to file?
Kazia Therapeutics Limited is required to file annual reports under cover of Form 20-F.
What is the SIC code for Kazia Therapeutics Limited?
The Standard Industrial Classification (SIC) code for Kazia Therapeutics Limited is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 287 words · 1 min read · ~1 pages · Grade level 12.6 · Accepted 2024-05-01 16:01:58
Filing Documents
- d830270d6k.htm (6-K) — 10KB
- d830270dex991.htm (EX-99.1) — 13KB
- g830270g0430102438644.jpg (GRAPHIC) — 4KB
- 0001193125-24-127428.txt ( ) — 29KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On May 1, 2024, Kazia Therapeutics Limited (the Company) issued a press release titled, Kazia Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend contained in Exhibit 99.1, into the Companys registration statement on Form F-3 (File No. 333-259224 and 333-276091). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated May 1, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 1 May 2024